Security Snapshot

Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) Institutional Ownership

CUSIP: 47103J105

13F Institutional Holders and Ownership History from Q2 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

142

Shares (Excl. Options)

44.19MFull value: 44,186,507 · shares · 30 Sep 2026

Price

$17.28

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-5,459,708
Value change
-$93,385,422
Number of holders
142
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
61,173,786
SEC-reported price per share
$17.28
Insider filing price
$17.28
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • JANX - Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 47103J105.
  • 142 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 193 to 142 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $933.37MFull value: $933,370,141 · USD · 30 Jun 2026
    to
    $763.66MFull value: $763,659,364 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 142 institutions filings for Q3 2026.

Open SEC evidence

Security key

47103J105

13F reference period

Q3 2026

13F holders

142

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
JANX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 20% $383,922,060 11,971,377 RA Capital Management, L.P. 06 Mar 2025
BlackRock, Inc. 6.7% +17% $62,952,300 +$11,562,900 4,098,457 +23% BlackRock, Inc. 30 Jun 2026
Prosight Management, LP 5.2% -3% $54,439,776 -$116,986 3,150,450 -0.21% W. Lawrence Hawkins 10 Nov 2026
Paradigm Biocapital Advisors LP 4.9% -18% $73,444,489 -$14,982,559 2,920,258 -17% Paradigm BioCapital Advisors LP 30 Jun 2025
FMR LLC 4.2% -27% $35,246,558 -$13,575,574 2,535,724 -28% FMR LLC 31 Mar 2026
Adage Capital Management, L.P. 4.3% -21% $63,503,750 -$13,499,262 2,525,000 -18% Adage Capital Management, L.P. 30 Jun 2025
STATE STREET CORP 4.1% -38% $34,249,836 -$19,320,083 2,464,017 -36% STATE STREET CORPORATION 31 Mar 2026
Point72 Asset Management, L.P. 3.3% -34% $32,200,468 -$17,376,140 1,993,837 -35% Point72 Asset Management, L.P. 30 Jun 2026
Janus Henderson Group Ltd. 0.3% -94% $2,781,498 -$64,990,507 172,229 -96% JANUS HENDERSON GROUP Ltd. 30 Jun 2026
As of 30 Sep 2026, 142 institutional investors reported holding
44.19MFull value: 44,186,507 · shares · 30 Sep 2026
shares of Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX). This represents 72% of the company’s total
61.17MFull value: 61,173,786 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
63%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 18% 11,189,693 1.9% $193,357,895
Prosight Management, LP 4.8% 2,943,200 9.9% $50,858,496
FEDERATED HERMES, INC. 4.2% 2,594,722 0.06% $44,836,796
STATE STREET CORP 3.8% 2,310,949 0% $39,933,199
VANGUARD CAPITAL MANAGEMENT LLC 3.5% 2,153,138 0% $37,206,225
TWO SIGMA INVESTMENTS, LP 3% 1,845,429 0.02% $31,889,013
TCG Crossover Management, LLC 2.9% 1,789,617 0.87% $30,924,582
Point72 Asset Management, L.P. 2.6% 1,579,984 0.04% $27,302,124
VANGUARD PORTFOLIO MANAGEMENT LLC 2.4% 1,452,698 0% $25,102,621
ALGERT GLOBAL LLC 2.3% 1,421,674 0.3% $24,566,527
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,281,018 0% $22,140,618
Alyeska Investment Group, L.P. 1.8% 1,095,401 0.05% $18,928,529
GOLDMAN SACHS GROUP INC 1.7% 1,027,073 0% $17,747,821
WELLINGTON MANAGEMENT GROUP LLP 1.5% 920,679 0% $15,909,333
Nantahala Capital Management, LLC 1.4% 857,334 0.83% $14,814,732
Qube Research & Technologies Ltd 1.1% 647,261 0.01% $11,184,670
ORBIMED ADVISORS LLC 0.86% 524,700 0.17% $9,066,816
BANK OF AMERICA CORP /DE/ 0.83% 506,368 0% $8,750,038
DIMENSIONAL FUND ADVISORS LP 0.72% 441,288 0% $7,625,021
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 0.62% 376,496 0.31% $6,505,851
Woodline Partners LP 0.61% 371,532 0.02% $6,420,073
Rock Springs Capital Management LP 0.6% 367,009 0.34% $6,341,916
Jump Financial, LLC 0.56% 344,611 0.05% $5,954,877
VANGUARD FIDUCIARY TRUST CO 0.54% 329,243 0% $5,689,319
Connor, Clark & Lunn Investment Management Ltd. 0.51% 312,051 0.01% $5,392,241

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
22
Headline period
Q3 2026
Rows shown
1-22 of 22
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 44,186,507 $763,659,364 -$93,385,422 $17.28 142
2026 Q2 60,787,798 $933,370,141 +$84,651,312 $15.36 193
2026 Q1 59,586,416 $827,823,706 -$45,211,811 $13.90 188
2025 Q4 62,149,272 $857,685,977 -$103,940,615 $13.80 173
2025 Q3 65,065,945 $1,590,036,358 -$3,819,977 $24.44 170
2025 Q2 65,389,958 $1,510,522,459 -$28,053,981 $23.10 169
2025 Q1 66,482,175 $1,805,570,973 -$17,647,630 $27.00 179
2024 Q4 64,089,510 $3,430,809,553 +$1,001,839,547 $53.54 213
2024 Q3 45,621,730 $2,072,353,785 +$42,332,014 $45.43 158
2024 Q2 44,723,442 $1,873,142,325 +$107,659,314 $41.89 153
2024 Q1 42,327,541 $1,593,608,078 +$334,250,630 $37.65 118
2023 Q4 33,501,695 $359,539,970 -$17,204,195 $10.73 64
2023 Q3 35,112,124 $353,984,587 +$45,518,472 $10.08 57
2023 Q2 30,508,831 $362,117,070 -$408,523 $11.87 54
2023 Q1 30,541,873 $369,527,936 +$18,629,245 $12.10 48
2022 Q4 28,954,042 $381,308,644 -$7,758,264 $13.17 49
2022 Q3 29,548,436 $400,093,845 +$8,918,649 $13.54 45
2022 Q2 28,911,820 $352,963,471 +$6,297,905 $12.21 43
2022 Q1 28,388,419 $407,113,023 +$11,406,319 $14.34 46
2021 Q4 27,496,946 $541,627,745 +$19,103,067 $19.73 46
2021 Q3 26,499,088 $571,208,440 +$35,499,490 $21.63 44
2021 Q2 24,743,225 $614,460,000 +$614,460,000 $24.95 29
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .